Gastroenterology

The new diet program was compared to the existing front-line therapy of exclusive enteral nutrition.

More than half of DAA prescriptions were prescribed by specialists like gastroenterologist and infectious disease physicians.

Fecal microbiota transplantation could be crucial in the coming years in treating C difficile infections.

IBD patients were less likely to have diets that regularly include vegetables, cereals, breads, and diary.

The cumulative time to curative treatment failure rates of patients who received DAA were 93.6% and 73.2% at 1 and 3 years, respectively.

Italy and the Netherlands both achieved their target HBV control.

Infants between 6-12 months old had the highest prevalence of C difficile detection.

Higher microbiome α diversity had an association with less T2D and lower insulin resistance in individuals without diabetes.

Data show no clinically meaningful difference between insulin glargine-yfgn and insulin glargine in matters of safety, purity and potency.

There was no association found between migraines and Crohn’s disease or ulcerative colitis.

The company expects to continue to study the potential inflammatory bowel disease treatment.

Genotype F was the common genotype found at 5.73 per 1000 person-years of follow-up.

Patients with IBD, rheumatoid arthritis, and psoriasis are commonly treated using biologic agents such as infliximab, tofacitinib, and ustekinumab.

The treatment was associated with an increased risk of C difficile colitis.

A recent study has found statins are underutilized for NASH and NAFLD patients.

The issuance comes within a week of the planned PDUFA date for the drug's possible indication as an adult CKD therapy.

The researchers found sero-protection rate at 12-month was significantly higher in the ID arm compared to the IM cohort.

This patient group was at an increased risk for future exposure to systemic corticosteroids and anti-TNF biologics.

Biologic use was not associated with an increased risk of hepatitis B virus flares.

Patients with IBD have an increased risk of developing a C difficile infection in comparison to the general population.

More than 56% of these patients enrolled in TARGET-NASH were being treated with statins.

About 25% of IBD patients with CDI had a history of antibiotic use.

One theory as to why IBD patients are more susceptible to CDI is the use of immunosuppressant treatments.

This edition of HCPLive® State of the Science involves 3 experts discussing different trends in IBD treatments and care.

96.4% of patients in symptomatic remission at week 152 were corticosteroid-free.